{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-076341","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.347941+00:00","generated_at":"2026-06-01T00:45:13.953962+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Gain Therapeutics CEO Alder departs; CFO Mack named interim CEO, Chairman Islam becomes Executive Chairman","bullets":["CEO Matthias Alder left June 25, 2024 to pursue other opportunities; separation includes 12 months salary, COBRA, accelerated vesting.","CFO Gene Mack appointed interim CEO effective June 25, 2024 and retains CFO role with no additional compensation.","Chairman Khalid Islam, PhD, named Executive Chairman to advise Mack until a permanent CEO is found.","Company's lead candidate GT-02287, an allosteric small molecule for Parkinson's, is in Phase 1 clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-076341","json":"https://secwatch.observer/filing/0001104659-24-076341.json","markdown":"https://secwatch.observer/filing/0001104659-24-076341.md","text":"https://secwatch.observer/filing/0001104659-24-076341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/0001104659-24-076341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/tm2418441d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:45:13.953962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20ef3a7dd2","claim":"Gene Mack was appointed as Interim Chief Executive Officer at Gain Therapeutics, Inc..","evidence_excerpt":"On June 27, 2024, Mr. Gene Mack (“Mr. Mack”), the Company’s current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer (“Interim CEO”), effective as June 25, 2024, to fill the vacancy created by Mr. Alder’s departure as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/0001104659-24-076341-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"765a8cc774","claim":"Matthias Alder was terminated as Chief Executive Officer at Gain Therapeutics, Inc..","evidence_excerpt":"On June 25, 2024, Matthias Alder (“Mr. Alder”), Chief Executive Officer of Gain Therapeutics, Inc. (the “Company”), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/0001104659-24-076341-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ff5f5df64a","claim":"Khalid Islam was appointed as Executive Chairman of the Board at Gain Therapeutics, Inc..","evidence_excerpt":"On June 27, 2024, Dr. Khalid Islam (“Dr. Islam”), the current Chairman of the Board, was appointed to serve as Executive Chairman of the Board, effective June 25, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/0001104659-24-076341-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}